INBX Inhibrx Inc.

28.15
+0.83  (+3%)
Previous Close 27.32
Open 26.97
52 Week Low 14.27
52 Week High 50.97
Market Cap $1,064,372,641
Shares 37,810,751
Float 22,429,710
Enterprise Value $1,005,398,973
Volume 262,931
Av. Daily Volume 253,875
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
INBRX-109
Chondrosarcoma and mesothelioma
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
INBRX-105 and KEYTRUDA (pembrolizumab)
Solid Tumors
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
INBRX-106
Solid Tumors
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
INBRX-101
Alpha-1 Antitrypsin Deficiency
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. SAN DIEGO, June 21, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma.

    INBRX-109 is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation.

    Chondrosarcoma is an orphan bone cancer with approximately 2,800 new patients diagnosed annually in the United States and the European Union. There are currently no therapeutics approved for the treatment of chondrosarcoma.

    In January 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.

    Inhibrx provided updated results from an ongoing Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with conventional chondrosarcoma. Additional data will be presented at the Annual Connective Tissue Oncology Society (CTOS) Conference taking place on November 10-13, 2021.

    • Disease control was observed in 14 of 16 patients (87.5%). Two patients (12.5%) achieved partial responses and 12 of 16 patients (75%) had stable disease measured by RECISTv1.1.
    • Based on preliminary results of the ongoing Phase 1 study, the median progression-free survival (PFS) is 7.6 months, and the median overall survival has not been reached.
    • Three patients have exceeded 52 weeks on treatment with INBRX-109, with 62 weeks being the longest duration of stable disease observed to date, with the patient still on study.
    • The safety and tolerability profile in conventional chondrosarcoma was favorable with only 1 out of 16 patients experiencing a transient low grade and fully reversible sign of hepatotoxicity.
    • The trial is ongoing with an additional 12 slots added for patients with IDH1 or IDH2 mutations to support ongoing biomarker discovery efforts.

    A randomized, blinded, placebo-controlled, potential registration-enabling Phase 2 trial of INBRX-109 in conventional chondrosarcoma initiated this month. The primary objective of this trial is to evaluate the anticancer efficacy of INBRX-109, as measured by PFS per RECISTv1.1 and assessed by central independent radiology review. Patients with disease progression on placebo will be able to crossover to INBRX-109. An interim analysis will occur after 50% of the planned PFS events are observed.

    Additionally, upon initiation of this study, Inhibrx's loan agreement with Oxford Finance was amended and $40M in additional principal was received by Inhibrx on June 18, 2021.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

    Forward-Looking Statements

    Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx's and its investigators' judgments and beliefs regarding the observed safety and efficacy to date of its therapeutic candidate, INBRX-109, discussions with and beliefs regarding future action by the U.S. Food and Drug Administration, and statements and beliefs regarding the future clinical development of INBRX-109 including statements indicating that the Phase 2 trial is registration-enabling and the presumption of positive results from Phase 1 clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its expectations regarding the impact of the COVID-19 pandemic on its business; and other risks described in Inhibrx's filings with the U.S. Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in Inhibrx's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains estimates and other statistical data made by independent parties and by Inhibrx. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

    Investor and Media Contact:

    Kelly Deck, CFO



    858-795-4260

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibrx-initiates-a-potential-registration-enabling-phase-2-study-of-inbrx-109-in-conventional-chondrosarcoma-patients-updates-data-for-ongoing-phase-1-study-and-announces-amended-loan-agreement-with-oxford-301316680.html

    SOURCE Inhibrx, Inc.

    View Full Article Hide Full Article
  2. SAN DIEGO, May 17, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conferences:

    • Jefferies Healthcare Conference; Wednesday, June 2nd at 12:30 p.m. Pacific Time
    • JMP Securities Life Sciences Conference; Thursday, June 17th at 8:00 a.m. Pacific Time

    The investor conference presentations will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The webcasts will be available for 60 days following the event.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

    Investor and Media Contact:

    Amy Conrad

    Juniper Point



    858-366-3243

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-investor-conferences-301291482.html

    SOURCE Inhibrx, Inc.

    View Full Article Hide Full Article
  3. SAN DIEGO, May 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, today reported financial results for the first quarter of 2021.

    "This past quarter, we continued to make significant progress advancing our clinical programs and are on track to deliver data from all four programs later this year," said the Company's Chief Executive Officer, Mark Lappe. "April 2021 marked 11 years of Inhibrx dedicated to developing novel, best-in-class therapeutics for the treatment of cancer and rare diseases, and we remain strongly encouraged that we will deliver on our mission."

    Financial Results

    • Cash and Cash Equivalents. As of March 31, 2021, Inhibrx had cash and cash equivalents of $108.0

    SAN DIEGO, May 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, today reported financial results for the first quarter of 2021.

    "This past quarter, we continued to make significant progress advancing our clinical programs and are on track to deliver data from all four programs later this year," said the Company's Chief Executive Officer, Mark Lappe. "April 2021 marked 11 years of Inhibrx dedicated to developing novel, best-in-class therapeutics for the treatment of cancer and rare diseases, and we remain strongly encouraged that we will deliver on our mission."

    Financial Results

    • Cash and Cash Equivalents. As of March 31, 2021, Inhibrx had cash and cash equivalents of $108.0 million, compared to $128.7 million as of December 31, 2020.
    • R&D Expense. Research and development expenses were $16.4 million during the first quarter of 2021, compared to $17.0 million during the first quarter of 2020. This overall decrease was primarily due to the timing of work performed by Inhibrx's contract development and manufacturing organization partners for the formulation and manufacturing of certain of its therapeutic candidates, offset in part by an increase in headcount and personnel-related costs due to the continued expansion of its organization.
    • G&A Expense. General and administrative expenses were $3.0 million during the first quarter of 2021, compared to $1.5 million during the first quarter of 2020. This increase was primarily due to an increase in personnel-related costs and other expenses associated with operating as a public company.
    • Net Loss. Net loss was $19.3 million during the first quarter of 2021, or $0.51 per share, compared to $20.1 million during the first quarter of 2020, or $1.11 per share.

    About the Inhibrx sdAb Platform

    Inhibrx utilizes diverse methods of protein engineering in the construction of therapeutic candidates that can address the specific requirements of complex target and disease biology. A key tool for this effort is the Inhibrx proprietary sdAb platform, which enables the development of therapeutic candidates with attributes superior to other monoclonal antibody and fusion protein approaches. This platform allows the combination of multiple binding units in a single molecule, enabling the creation of therapeutic candidates with defined valency or multiple specificities that can achieve enhanced cell signaling or conditional activation. An additional benefit of this platform is that these optimized, multi-functional entities can be manufactured using the established processes that are commonly used to produce therapeutic proteins.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

    Forward Looking Statements

    Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: future clinical development Inhibrx's therapeutic candidates, including statements regarding expected therapeutic benefit, the timing of future clinical development and evaluations and judgments regarding Inhibrx's therapeutic candidates. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its expectations regarding the impact of the COVID-19 pandemic on its business; and other risks described in Inhibrx's filings with the U.S. Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in Inhibrx's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Investor and Media Contact:

    Amy Conrad

    Juniper Point



    858-366-3243

     

    Inhibrx, Inc.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share data)







    THREE MONTHS ENDED MARCH 31,



    2021



    2020



    (unaudited)

    Revenue:







    License fee revenue

    $

    863





    $

    872



    Grant revenue

    26







    Total revenue

    889





    872



    Operating expenses:







    Research and development

    16,438





    17,016



    General and administrative

    3,009





    1,467



    Total operating expenses

    19,447





    18,483



    Loss from operations

    (18,558)





    (17,611)



    Total other income (expense)

    (729)





    (2,482)



    Provision for income taxes

    2







    Net loss

    $

    (19,289)





    $

    (20,093)



    Net loss per share, basic and diluted

    $

    (0.51)





    $

    (1.11)



    Weighted-average shares of common stock outstanding, basic and diluted

    37,736





    18,154



     



     

    Inhibrx, Inc.

    Condensed Consolidated Balance Sheets

    (In thousands) 











    MARCH 31,



    DECEMBER 31,



    2021



    2020



    (unaudited)













    Cash and cash equivalents

    $

    107,990





    $

    128,664



    Other current assets

    5,412





    3,508



    Non-current assets

    11,102





    11,568



    Total assets

    $

    124,504





    $

    143,740











    Debt, current and non-current

    $

    29,445





    $

    29,244



    Other current liabilities

    27,850





    31,399



    Other non-current liabilities

    6,616





    7,624



    Total liabilities

    63,911





    68,267



    Stockholders' equity

    60,593





    75,473



    Total liabilities and stockholders' equity

    $

    124,504





    $

    143,740



     

    Cision View original content:http://www.prnewswire.com/news-releases/inhibrx-reports-first-quarter-2021-financial-results-301290427.html

    SOURCE Inhibrx, Inc.

    View Full Article Hide Full Article
  4. SAN DIEGO, March 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and announced results from the single agent dose escalation of the Phase 1 study of INBRX-105.

    Mark Lappe, Inhibrx's CEO commented, "2020 was a transformative year for Inhibrx. We made substantive advances in our four clinical programs across oncology and orphan disease, continued to progress our pre-clinical pipeline, and successfully completed an initial public offering."

    Phase 1 Dose Escalation Results for INBRX-105

    INBRX-105 is a precisely engineered multi-specific therapeutic candidate based on our single domain antibody (sdAb…

    SAN DIEGO, March 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and announced results from the single agent dose escalation of the Phase 1 study of INBRX-105.

    Mark Lappe, Inhibrx's CEO commented, "2020 was a transformative year for Inhibrx. We made substantive advances in our four clinical programs across oncology and orphan disease, continued to progress our pre-clinical pipeline, and successfully completed an initial public offering."

    Phase 1 Dose Escalation Results for INBRX-105

    INBRX-105 is a precisely engineered multi-specific therapeutic candidate based on our single domain antibody (sdAb) platform that is designed to agonize 4-1BB selectively in the presence of programmed death ligand 1 (PD-L1), a protein that is typically found in the tumor microenvironment and lymphoid tissues.

    The study is a first-in-human, multicenter, open-label, non-randomized, Phase 1 trial in patients with locally advanced or metastatic solid tumors. The trial is designed to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of INBRX-105 administered as a single agent or in combination with Keytruda® (pembrolizumab), a programmed death receptor-1 (PD-1) checkpoint inhibitor. Single agent dose escalation was completed with a total of 32 patients enrolled. We observed dose-limiting toxicities, which were consistent with immune related adverse events (for example, hepatitis, arthritis and myalgia/hyperthyroidism) at several dose levels and determined the 1 mg/kg dose level as the MTD of INBRX-105. Patients were not pre-screened for PD-L1 expression. Eight out of 18 evaluable patients (44%) receiving INBRX-105 at dose levels equal to or greater than 0.1 mg/kg achieved stable disease, with the greatest reduction in tumor volume observed to be 20% by RECISTv1.1. The longest duration on treatment with INBRX-105 was 41 weeks, or approximately nine and a half months. Notably, seven patients with stable disease tested positive for PD-L1 expression, with a minimum of 1% positivity as determined by immunohistochemistry (Range 1 to 95%), and the results of one patient are pending. Four of these eight patients were refractory to or progressed on prior PD-1 checkpoint inhibitors.

    We expect to achieve the maximal therapeutic benefit of INBRX-105 in combination with PD-1 checkpoint blockade. In our preclinical studies we observed that acute exposure to PD-L1 dependent 4-1BB agonism was sufficient to derive maximal anti-tumor activity when co-dosed with another PD-1 blocking agent at a target saturating dose. As such, a dose escalation cohort of INBRX-105 in combination with Keytruda® is targeted to initiate enrollment during the second quarter of 2021 and we expect to announce initial data during the fourth quarter of 2021.

    Financial Results

    • Cash and Cash Equivalents. Cash and cash equivalents totaled $128.7 million as of December 31, 2020, compared to $11.5 million as of December 31, 2019. Cash and cash equivalents totaled $111.3 million as of February 28, 2021.
    • R&D Expense. Research and development expense was $17.7 million during the fourth quarter of 2020, as compared to $12.3 million during the fourth quarter of 2019. Research and development expense was $73.5 million during the fiscal year 2020, as compared to $47.9 million during the fiscal year 2019.  These increases were primarily due to an increase in contract manufacturing expense for scale-up activities performed by Inhibrx's contract development and manufacturing organization partners for its INBRX-109 and INBRX-101 programs. Additionally, clinical research organization costs increased due to the progression of its Phase 1 trials.
    • G&A Expense. General and administrative, or G&A, expense was $2.2 million during the fourth quarter of 2020, as compared to $1.7 million during the fourth quarter of 2019. G&A expense was $6.8 million during the fiscal year 2020, as compared to $6.3 million during the fiscal year 2019. These increases were primarily due to increases in Inhibrx's personnel-related expenses due to increased headcount and increased rent expense under its amended building lease.
    • Net Loss. Net loss was $17.6 million during the fourth quarter of 2020, or a net loss per share of $0.47, as compared to a net loss of $16.3 million during the fourth quarter of 2019, or a net loss per share of $0.90. Net loss was $76.1 million during the fiscal year 2020, or a net loss per share of $3.01, as compared to a net loss of $51.4 million during the fiscal year 2019, or a net loss per share of $2.83.

    Inhibrx Corporate Presentation

    Inhibrx has also updated its corporate presentation which is available on the "Investors" section of its website at www.inhibrx.com.

    About the Inhibrx sdAb Platform

    Inhibrx utilizes diverse methods of protein engineering in the construction of therapeutic candidates that can address the specific requirements of complex target and disease biology. A key tool for this effort is the Inhibrx proprietary sdAb platform, which enables the development of therapeutic candidates with attributes superior to other monoclonal antibody and fusion protein approaches. This platform allows the combination of multiple binding units in a single molecule, enabling the creation of therapeutic candidates with defined valency or multiple specificities that can achieve enhanced cell signaling or conditional activation. An additional benefit of this platform is that these optimized, multi-functional entities can be manufactured using the established processes that are commonly used to produce therapeutic proteins.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

    Forward Looking Statements

    Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: future clinical development Inhibrx's therapeutic candidates, including statements regarding expected therapeutic benefit, the timing of future clinical development and evaluations and judgments regarding Inhibrx's therapeutic candidates. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its expectations regarding the impact of the COVID-19 pandemic on its business; and other risks described in Inhibrx's filings with the U.S. Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in Inhibrx's Quarterly Report on Form 10-Q for the period ended September 30, 2020, as filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Investor and Media Contact:

    Amy Conrad

    Juniper Point



    858-366-3243



    Inhibrx, Inc

    Condensed Consolidated Statements of Operations

    (In thousands, except per share data)





    THREE MONTHS ENDED DECEMBER 31,



    YEAR ENDED

    DECEMBER 31,



    2020



    2019



    2020



    2019

    Revenue:















    License fee revenue

    $

    2,776





    $

    267





    $

    12,808





    $

    9,093



    Grant revenue





    (4)





    80





    4,118



    Total revenue

    2,776





    263





    12,888





    13,211



    Operating expenses:















    Research and development

    17,668





    12,283





    73,495





    47,907



    General and administrative

    2,215





    1,673





    6,836





    6,257



    Abandoned offering costs





    2,761









    2,761



    Total operating expenses

    19,883





    16,717





    80,331





    56,925



    Loss from operations

    (17,107)





    (16,454)





    (67,443)





    (43,714)



    Total other income (expense)

    (539)





    149





    (8,191)





    (6,788)



    Provision for income taxes

    3









    3





    898



    Loss on equity method investment









    487







    Net loss

    (17,649)





    (16,305)





    $

    (76,124)





    $

    (51,400)



    Net loss per share, basic and diluted

    $

    (0.47)





    $

    (0.90)





    $

    (3.01)





    $

    (2.83)



    Weighted-average shares of common stock outstanding, basic and diluted

    37,712





    18,154





    25,261





    18,154









    Inhibrx, Inc

    Condensed Consolidated Balance Sheets

    (In thousands)





    AS OF DECEMBER 31,



    2020



    2019









    Cash and cash equivalents

    $

    128,664





    $

    11,540



    Other current assets

    3,508





    4,021



    Non-current assets

    11,568





    10,928



    Total assets

    $

    143,740





    26,489











    Debt, current and non-current

    $

    29,244





    $

    3,563



    Other current liabilities

    31,399





    17,007



    Convertible notes





    30,367



    Other non-current liabilities

    7,624





    9,614



    Total liabilities

    68,267





    60,551



    Convertible preferred stock





    59,507



    Stockholders' equity (deficit)

    75,473





    (93,569)



    Total liabilities, convertible preferred stock and stockholders' equity (deficit)

    $

    143,740





    $

    26,489



     

    Cision View original content:http://www.prnewswire.com/news-releases/inhibrx-reports-fourth-quarter-and-fiscal-year-2020-financial-results-and-announces-phase-1-single-agent-dose-escalation-results-for-inbrx-105-a-novel-targeted-4-1bb-agonist-301245665.html

    SOURCE Inhibrx, Inc.

    View Full Article Hide Full Article
  5. SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference:

    • Guggenheim Healthcare Talks: 2021 Oncology Days; Friday, February 12th, at 2 p.m. Pacific Time

    The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The webcast will be available for 60 days following the event.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing…

    SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference:

    • Guggenheim Healthcare Talks: 2021 Oncology Days; Friday, February 12th, at 2 p.m. Pacific Time

    The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The webcast will be available for 60 days following the event.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

    Investor and Media Contact:

    Amy Conrad

    Juniper Point



    858-366-3243

    Cision View original content:http://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-investor-conference-301219478.html

    SOURCE Inhibrx, Inc.

    View Full Article Hide Full Article
View All Inhibrx Inc. News